[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Contempo 1998
July 1, 1998

Prevention and Treatment of Pediatric HIV Infection

Author Affiliations

From the Department of Pediatrics and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester.


Edited by Ronna Henry Siegel, MD, Contributing Editor.

JAMA. 1998;280(1):17-18. doi:10.1001/jama.280.1.17

AS OF December 1997, more than 30 million individuals throughout the world were infected with human immunodeficiency virus 1 (HIV-1).1 Of the estimated 16000 new infections that occur daily, more than 90% occur in developing countries, and 40% occur in women of childbearing age. Every minute of the day an infant is born infected with HIV-1. In sub-Saharan Africa, 6% to 30% of pregnant women are HIV-1 seropositive. In the United States, 0.17% of all childbearing women are seropositive, and 6000 to 7000 infants are born each year to HIV-1–seropositive women.2,3 Particularly high HIV-1 seroprevalence rates have been documented in pregnant women in inner-city populations of New York City (1.25%), the District of Columbia (0.9%), Puerto Rico (0.7%), New Jersey (0.56%), and Florida (0.54%).3 Although HIV-1 seroprevalence rates in childbearing women in the United States have leveled recently, there has been an increase in the incidence of HIV infection among adolescent girls, primarily through heterosexual transmission.4